CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells

  • Authors:
    • Nobuyuki Ishikura
    • Hiromitsu Kawata
    • Ayako Nishimoto
    • Ryo Nakamura
    • Toshiaki Tsunenari
    • Miho Watanabe
    • Kazutaka Tachibana
    • Takuya Shiraishi
    • Hitoshi Yoshino
    • Akie Honma
    • Takashi Emura
    • Masateru Ohta
    • Toshito Nakagawa
    • Takao Houjo
    • Eva Corey
    • Robert L. Vessella
    • Yuko Aoki
    • Haruhiko Sato
  • View Affiliations

  • Published online on: January 30, 2015     https://doi.org/10.3892/ijo.2015.2860
  • Pages: 1560-1572
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Resistance of prostate cancer to castration is currently an unavoidable problem. The major mechanisms underlying such resistance are androgen receptor (AR) overexpression, androgen-independent activation of AR, and AR mutation. To address this problem, we developed an AR pure antagonist, CH5137291, with AR nuclear translocation-inhibiting activity, and compared its activity and characteristics with that of bicalutamide. Cell lines corresponding to the mechanisms of castration resistance were used: LNCaP-BC2 having AR overexpression and LNCaP-CS10 having androgen-independent AR activation. VCaP and LNCaP were used as hormone-sensitive prostate cancer cells. In vitro functional assay clearly showed that CH5137291 inhibited the nuclear translocation of wild-type ARs as well as W741C- and T877A-mutant ARs. In addition, it acted as a pure antagonist on the transcriptional activity of these types of ARs. In contrast, bicalutamide did not inhibit the nuclear translocation of these ARs, and showed a partial/full agonistic effect on the transcriptional activity. CH5137291 inhibited cell growth more strongly than bicalutamide in VCaP and LNCaP cells as well as in LNCaP-BC2 and LNCaP-CS10 cells in vitro. In xenograft models, CH5137291 strongly inhibited the tumor growth of LNCaP, LNCaP-BC2, and LNCaP-CS10, whereas bicalutamide showed a weaker effect in LNCaP and almost no effect in LNCaP-BC2 and LNCaP-CS10 xenografts. Levels of prostate-specific antigen (PSA) in plasma correlated well with the antitumor effect of both agents. CH5137291 inhibited the growth of LNCaP tumors that had become resistant to bicalutamide treatment. A docking model suggested that CH5137291 intensively collided with the M895 residue of helix 12, and therefore strongly inhibited the folding of helix 12, a cause of AR agonist activity, in wild-type and W741C-mutant ARs. In cynomolgus monkeys, the serum concentration of CH5137291 increased dose-dependently and PSA level decreased 80% at 100 mg/kg. CH5137291 is expected to offer a novel therapeutic approach against major types of castration-resistant prostate cancers.
View Figures
View References

Related Articles

Journal Cover

April 2015
Volume 46 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ishikura, N., Kawata, H., Nishimoto, A., Nakamura, R., Tsunenari, T., Watanabe, M. ... Sato, H. (2015). CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells. International Journal of Oncology, 46, 1560-1572. https://doi.org/10.3892/ijo.2015.2860
MLA
Ishikura, N., Kawata, H., Nishimoto, A., Nakamura, R., Tsunenari, T., Watanabe, M., Tachibana, K., Shiraishi, T., Yoshino, H., Honma, A., Emura, T., Ohta, M., Nakagawa, T., Houjo, T., Corey, E., Vessella, R. L., Aoki, Y., Sato, H."CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells". International Journal of Oncology 46.4 (2015): 1560-1572.
Chicago
Ishikura, N., Kawata, H., Nishimoto, A., Nakamura, R., Tsunenari, T., Watanabe, M., Tachibana, K., Shiraishi, T., Yoshino, H., Honma, A., Emura, T., Ohta, M., Nakagawa, T., Houjo, T., Corey, E., Vessella, R. L., Aoki, Y., Sato, H."CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells". International Journal of Oncology 46, no. 4 (2015): 1560-1572. https://doi.org/10.3892/ijo.2015.2860